

Kwee L Yong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5500283/publications.pdf>

Version: 2024-02-01

237
papers

8,183
citations

66343

42
h-index

54911

84
g-index

238
all docs

238
docs citations

238
times ranked

8490
citing authors

#	ARTICLE	IF	CITATIONS
1	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695
2	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 2096-2107.	13.7	435
3	High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. <i>Blood</i> , 2002, 99, 4357-4363.	1.4	349
4	Multiple myeloma. <i>Lancet</i> , The, 2021, 397, 410-427.	13.7	349
5	Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. <i>Blood</i> , 2002, 99, 1071-1078.	1.4	333
6	Guidelines for the diagnosis and management of multiple myeloma 2011. <i>British Journal of Haematology</i> , 2011, 154, 32-75.	2.5	252
7	Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. <i>Blood</i> , 2002, 100, 3121-3127.	1.4	236
8	Multiple myeloma: patient outcomes in real-world practice. <i>British Journal of Haematology</i> , 2016, 175, 252-264.	2.5	220
9	Different Proliferative Potential and Migratory Characteristics of Human CD4+ Regulatory T Cells That Express either CD45RA or CD45RO. <i>Journal of Immunology</i> , 2010, 184, 4317-4326.	0.8	205
10	Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. <i>Blood</i> , 2004, 103, 1548-1556.	1.4	193
11	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1641-1653.	10.7	193
12	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2021, 397, 2361-2371.	13.7	177
13	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	1.4	146
14	High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Tj ETQq0 0 0 rgBT/Overlock 10 Tf 5 15, 874-885.	10.7	139
15	Maturation of DC is associated with changes in motile characteristics and adherence. <i>Cytoskeleton</i> , 2004, 57, 118-132.	4.4	137
16	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
17	An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. <i>Blood</i> , 2018, 131, 746-758.	1.4	131
18	Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. <i>British Journal of Haematology</i> , 2016, 174, 911-922.	2.5	122

#	ARTICLE	IF	CITATIONS
19	The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2016, 3, e340-e351.	4.6	120
20	Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. <i>Haematologica</i> , 2008, 93, 1457-1465.	3.5	113
21	Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. <i>British Journal of Haematology</i> , 2005, 129, 763-770.	2.5	112
22	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	1.6	110
23	Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 1760-1772.	10.7	109
24	Transmigration of CD34+ Cells Across Specialized and Nonspecialized Endothelium Requires Prior Activation by Growth Factors and Is Mediated by PECAM-1 (CD31). <i>Blood</i> , 1998, 91, 1196-1205.	1.4	99
25	Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 186-194.	2.0	93
26	Multiple myeloma: practice patterns across Europe. <i>British Journal of Haematology</i> , 2016, 175, 66-76.	2.5	91
27	Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 257-265.	2.0	89
28	Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4+ α CD45RA+ α CD27 α T cells: the potential involvement of interleukin-7 in this process. <i>Immunology</i> , 2011, 132, 326-339.	4.4	85
29	Differential effects of granulocyte and granulocyte macrophage colony stimulating factors (G-CSF and Tj ETQq1 1 0.784314 rgB). <i>Immunology</i> , 1992, 49, 251-259.	2.2	76
30	Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. <i>British Journal of Haematology</i> , 2002, 119, 1125-1132.	2.5	74
31	Multiple myeloma. <i>BMJ</i> , 2013, 346, f3863-f3863.	6.0	64
32	Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. <i>European Radiology</i> , 2017, 27, 5325-5336.	4.5	62
33	Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. <i>Future Oncology</i> , 2020, 16, 4347-4358.	2.4	60
34	In vivo effects of macrophage colony-stimulating factor on human monocyte function. <i>British Journal of Haematology</i> , 1991, 77, 25-31.	2.5	59
35	Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo or immunotherapy. <i>British Journal of Haematology</i> , 2020, 191, 194-206.	2.5	58
36	Impaired bone marrow homing of cytokine-activated CD34+ cells in the NOD/SCID model. <i>Blood</i> , 2004, 103, 2079-2087.	1.4	55

#	ARTICLE	IF	CITATIONS
37	A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. <i>BMC Cancer</i> , 2013, 13, 31.	2.6	52
38	APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. <i>Blood</i> , 2011, 117, 890-901.	1.4	50
39	Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. <i>Journal of Gene Medicine</i> , 2006, 8, 253-264.	2.8	49
40	Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. <i>Supportive Care in Cancer</i> , 2013, 21, 599-607.	2.2	48
41	Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. <i>British Journal of Haematology</i> , 2017, 176, 222-233.	2.5	48
42	T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor ly. <i>British Journal of Haematology</i> , 2003, 123, 309-322.	2.5	44
43	Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. <i>British Journal of Haematology</i> , 2017, 176, 888-907.	2.5	44
44	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021, 35, 562-572.	7.2	43
45	Multiple myeloma and physical activity: a scoping review. <i>BMJ Open</i> , 2015, 5, e009576.	1.9	40
46	Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. <i>Haematologica</i> , 2020, 105, e261-e263.	3.5	40
47	Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. <i>Lancet Haematology</i> , 2016, 3, e572-e580.	4.6	39
48	Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. <i>Haematologica</i> , 2004, 89, 435-43.	3.5	39
49	Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS [®] (v2 ^Â 1) and Isolex [®] 300i (v2 ^Â 5) clinical scale devices. <i>British Journal of Haematology</i> , 2002, 118, 117-123.	2.5	38
50	Reconstitution of T-cell repertoire after autologous stem cell transplantation: Influence of CD34 selection and cytomegalovirus infection. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 198-205.	2.0	38
51	Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 3112-3112.	1.4	38
52	Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. <i>British Journal of Haematology</i> , 2019, 187, 638-641.	2.5	35
53	Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design. <i>British Journal of Cancer</i> , 2020, 123, 187-195.	6.4	35
54	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.7	33

#	ARTICLE	IF	CITATIONS
55	Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 3443-3454.	7.0	33
56	Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159. <i>Blood</i> , 2017, 130, 741-741.	1.4	33
57	Patients with Lymphoplasmacytic Lymphoma Can Be Salvaged with Autologous Stem Cell Transplantation, Irrespective of the Number of Previous Treatment Lines. Analysis of 146 Cases from the European Bone Marrow Transplant Registry (EBMT).. <i>Blood</i> , 2004, 104, 11-11.	1.4	33
58	Bortezomibâ€nduced inflammatory neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2010, 15, 366-368.	3.1	32
59	Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. <i>Blood</i> , 2014, 123, 2513-2517.	1.4	32
60	Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24. <i>Clinical Cancer Research</i> , 2005, 11, 3377-3384.	7.0	31
61	Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 120, 154-165.	2.5	30
62	Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. <i>British Journal of Cancer</i> , 2016, 114, 7-13.	6.4	30
63	Differential expression of CD180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. <i>British Journal of Haematology</i> , 2005, 131, 313-319.	2.5	28
64	Deferred autologous stem cell transplantation in systemic AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 101.	6.2	28
65	Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma. <i>PLoS ONE</i> , 2012, 7, e41127.	2.5	28
66	Engraftment defect of cytokineâ€cultured adult human mobilized <sc>CD</sc>34⁺ cells is related to reduced adhesion to bone marrow niche elements. <i>British Journal of Haematology</i> , 2012, 158, 778-787.	2.5	27
67	Advances in understanding prognosis in myeloma. <i>British Journal of Haematology</i> , 2016, 175, 367-380.	2.5	27
68	Subgroup analysis of ICARIAâ€MM study in relapsed/refractory multiple myeloma patients with highâ€risk cytogenetics. <i>British Journal of Haematology</i> , 2021, 194, 120-131.	2.5	27
69	Multiple myeloma presenting with spinal cord compression during pregnancy. <i>Annals of Hematology</i> , 2009, 88, 181-182.	1.8	25
70	Realâ€world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multiâ€centre <sc>UK</sc> experience. <i>British Journal of Haematology</i> , 2017, 176, 908-917.	2.5	25
71	Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid lightâ€chain amyloidosis. <i>British Journal of Haematology</i> , 2020, 189, 643-649.	2.5	25
72	Raised VEGF. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e486.	6.0	24

#	ARTICLE	IF	CITATIONS
73	Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1617-1628.	1.6	24
74	Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. <i>European Journal of Haematology</i> , 2019, 103, 107-115.	2.2	23
75	Pentoxifylline at clinically achievable levels inhibits FMLP-induced neutrophil responses, but not priming, upregulation of cell adhesion molecules, or migration induced by GM-CSF. <i>European Journal of Haematology</i> , 1993, 50, 1-10.	2.2	22
76	Global hypomethylation in myeloma is associated with poor prognosis. <i>British Journal of Haematology</i> , 2016, 172, 473-475.	2.5	21
77	Dendritic cells and myeloid leukaemias: plasticity and commitment in cell differentiation. <i>British Journal of Haematology</i> , 2007, 138, 281-290.	2.5	20
78	Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. <i>Leukemia</i> , 2012, 26, 1761-1770.	7.2	20
79	Updates to the guidelines for the diagnosis and management of multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 131-133.	2.5	20
80	Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients. <i>Blood</i> , 2017, 130, 903-903.	1.4	20
81	The effect of macrophage colony-stimulating factor on haemopoietic recovery after autologous bone marrow transplantation. <i>British Journal of Haematology</i> , 1992, 81, 288-295.	2.5	19
82	Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKONE randomized dose selection trial. <i>British Journal of Haematology</i> , 2015, 170, 336-348.	2.5	19
83	Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing. <i>BMC Cancer</i> , 2016, 16, 444.	2.6	19
84	Time to redefine Myeloma. <i>British Journal of Haematology</i> , 2015, 171, 1-10.	2.5	18
85	RAS mutation status and bortezomib therapy for relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2015, 169, 905-908.	2.5	18
86	Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. <i>British Journal of Haematology</i> , 2019, 185, 981-984.	2.5	18
87	Myeloma impairs mature osteoblast function but causes early expansion of osteoprogenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. <i>British Journal of Haematology</i> , 2016, 172, 64-79.	2.5	17
88	Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1926-1937.	2.0	16
89	Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. <i>Clinical Drug Investigation</i> , 2022, 42, 29-41.	2.2	16
90	Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells. <i>British Journal of Haematology</i> , 2007, 139, 243-254.	2.5	15

#	ARTICLE	IF	CITATIONS
91	The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation <i>in vitro</i> : defining the stromal defect in myeloma. <i>British Journal of Haematology</i> , 2014, 167, 194-206.	2.5	15
92	The start of a new wave: Developments in proteasome inhibition in multiple myeloma. <i>European Journal of Haematology</i> , 2018, 101, 220-236.	2.2	15
93	Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. <i>Journal of Medical Economics</i> , 2018, 21, 450-467.	2.1	15
94	Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. <i>Journal of Bone Oncology</i> , 2019, 17, 100243.	2.4	15
95	PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma. <i>BMJ Open</i> , 2020, 10, e033176.	1.9	15
96	Fetal haemopoietic cells display enhanced migration across endothelium. <i>British Journal of Haematology</i> , 2002, 116, 392-400.	2.5	14
97	Influence of cell cycling and cell division on transendothelial migration of CD34+ cells. <i>British Journal of Haematology</i> , 2002, 119, 500-509.	2.5	14
98	Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. <i>British Journal of Haematology</i> , 2004, 125, 756-765.	2.5	14
99	Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. <i>Leukemia and Lymphoma</i> , 2014, 55, 1661-1662.	1.3	14
100	RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. <i>Blood</i> , 2018, 132, 2154-2165.	1.4	14
101	The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT / UKMF Myeloma X) <i>TJ ETO</i> 2.5 1 0.784314 rgB 450-467.	2.5	14
102	Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. <i>Annals of Hematology</i> , 2015, 94, 643-649.	1.8	13
103	Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. <i>EJHaem</i> , 2022, 3, 97-108.	1.0	13
104	Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 200-205.	3.0	12
105	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1. <i>Blood</i> , 2011, 118, 3976-3976.	1.4	12
106	CD20-positive multiple myeloma " differential expression of cyclins D1 and D2 suggests a heterogeneous disease. <i>British Journal of Haematology</i> , 2010, 149, 156-159.	2.5	11
107	Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma. <i>European Journal of Haematology</i> , 2013, 90, 420-425.	2.2	11
108	Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors. <i>British Journal of Haematology</i> , 2021, 196, e21.	2.5	11

#	ARTICLE	IF	CITATIONS
109	Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. <i>Nature Communications</i> , 2022, 13, .	12.8	11
110	Microvasculitic paraproteinaemic polyneuropathy and B-cell lymphoma. <i>Journal of the Peripheral Nervous System</i> , 2003, 8, 100-107.	3.1	10
111	Multiple myeloma and physical activity. <i>BMC Research Notes</i> , 2021, 14, 171.	1.4	9
112	Interleukin-3 administration enhances human monocyte function in vivo. <i>British Journal of Haematology</i> , 1994, 88, 515-519.	2.5	8
113	Myeloma presenting during pregnancy. <i>Hematological Oncology</i> , 2014, 32, 52-55.	1.7	8
114	Cohort analysis of FISH testing of CD138 ⁺ cells in relapsed multiple myeloma: implications for prognosis and choice of therapy. <i>British Journal of Haematology</i> , 2015, 171, 881-883.	2.5	8
115	Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1009-1016.	2.0	8
116	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. <i>Hematological Oncology</i> , 2017, 35, 432-439.	1.7	8
117	The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. <i>Trials</i> , 2018, 19, 169.	1.6	8
118	Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (<sc>MUK</sc> six open label, multi-centre phase I/II Clinical Trial). <i>British Journal of Haematology</i> , 2019, 185, 573-578.	2.5	8
119	Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. <i>British Journal of Haematology</i> , 2021, 193, 750-760.	2.5	8
120	The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface. <i>PLoS ONE</i> , 2014, 9, e103254.	2.5	8
121	Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study. <i>Thrombosis Research</i> , 2022, 213, 27-29.	1.7	8
122	Evaluation of the Taguchi methods for the simultaneous assessment of the effects of multiple variables in the tumour microenvironment. <i>International Seminars in Surgical Oncology</i> , 2004, 1, 7.	1.1	7
123	The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. <i>BMC Hematology</i> , 2016, 16, 14.	2.6	7
124	COVID-19 and myeloma clinical research – experience from the CARDAMON clinical trial. <i>British Journal of Haematology</i> , 2021, 192, e14-e16.	2.5	7
125	Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 618610.	4.8	7
126	Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study. <i>Blood</i> , 2019, 134, 861-861.	1.4	7

#	ARTICLE	IF	CITATIONS
127	Improved response with postâ€ ^{sc} ASCTâ€ ^{sc} consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma. British Journal of Haematology, 2012, 158, 499-505.	2.5	6
128	Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. British Journal of Haematology, 2021, 192, 997-1005.	2.5	6
129	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKâ€ ⁱ fiveâ€ ⁱ). Haematologica, 2021, 106, 2694-2706.	3.5	6
130	Physical Activity During and After Haematological Cancer Treatment: A Cross-Sectional Survey of Haematology Healthcare Professionals in the United Kingdom. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 1659-1671.	2.7	6
131	Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma. Frontiers in Oncology, 2021, 11, 703233.	2.8	6
132	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. Future Oncology, 2021, 17, 4797-4812.	2.4	6
133	Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease. Blood, 2018, 132, 802-802.	1.4	6
134	Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study. Blood, 2017, 130, 835-835.	1.4	6
135	Myeloma patientsâ€™ experiences of a supervised physical activity programme: a qualitative study. Supportive Care in Cancer, 2022, 30, 6273-6286.	2.2	6
136	Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2854-2864.	7.0	6
137	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: â€ ^{sc} IKEMAâ€ ^{sc} subgroup analysis. American Journal of Hematology, 2023, 98, .	4.1	6
138	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematological Oncology, 2022, 40, 1020-1029.	1.7	6
139	Selective migration of highly differentiated primed T cells across human umbilical vein endothelial cells. Biochemical Society Transactions, 1997, 25, 258S-258S.	3.4	5
140	Cyclin D type does not influence cell cycle response to â€ ^{sc} DNAâ€ ^{sc} damage caused by ionizing radiation in multiple myeloma tumours. British Journal of Haematology, 2016, 173, 693-704.	2.5	5
141	National survey of imaging practice for suspected or confirmed plasma cell malignancies. British Journal of Radiology, 2018, 91, 20180462.	2.2	5
142	A realâ€ ^w orld study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multipleâ€ ^m yeloma patients. British Journal of Haematology, 2020, 191, 927-930.	2.5	5
143	Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set. Leukemia and Lymphoma, 2021, 62, 1243-1246.	1.3	5
144	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.. Journal of Clinical Oncology, 2021, 39, 8026-8026.	1.6	5

#	ARTICLE	IF	CITATIONS
145	Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).. Journal of Clinical Oncology, 2021, 39, 8000-8000.	1.6	5
146	Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.. Journal of Clinical Oncology, 2021, 39, 8042-8042.	1.6	5
147	The adapted Zelen was a feasible design to trial exercise in myeloma survivors. Journal of Clinical Epidemiology, 2020, 125, 76-83.	5.0	5
148	Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial. British Journal of Haematology, 2013, 163, 541-543.	2.5	4
149	An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma. British Journal of Haematology, 2015, 168, 148-151.	2.5	4
150	Oral proteasome inhibitor maintenance for multiple myeloma. Lancet, The, 2019, 393, 204-205.	13.7	4
151	Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. Blood, 2018, 132, 255-255.	1.4	4
152	17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management. Hematological Oncology, 2016, 34, 165-170.	1.7	3
153	More convenient proteasome inhibition for improved outcomes. Lancet Oncology, The, 2018, 19, 856-858.	10.7	3
154	Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?. Haematologica, 2019, 104, 2128-2131.	3.5	3
155	Bortezomib consolidation postâ€ASCT as frontline therapy for multiple myeloma deepens disease response and MRDâ€negative rate whilst maintaining QOL and response to reâ€treatment at relapse. British Journal of Haematology, 2019, 185, 948-951.	2.5	3
156	Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. British Journal of Haematology, 2020, 190, e312-e316.	2.5	3
157	DTâ€PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. British Journal of Haematology, 2021, 192, e73-e77.	2.5	3
158	Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. British Journal of Haematology, 2021, 193, e19-e22.	2.5	3
159	Development of antibody response to SARSâ€CoVâ€2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy. British Journal of Haematology, 2021, 194, 857-861.	2.5	3
160	Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study. Blood, 2018, 132, 306-306.	1.4	3
161	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 2019, 23, 1-94.	2.8	3
162	Role of Allogeneic Stem Cell Transplantation in Lymphoplasmacytic Lymphoma. Analysis of 61 Cases from the European Bone Marrow Registry (EBMT).. Blood, 2004, 104, 3326-3326.	1.4	3

#	ARTICLE	IF	CITATIONS
163	Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression. <i>British Journal of Haematology</i> , 2022, 196, .	2.5	3
164	Daratumumab, Bortezomib and Dexamethasone (DvD) at First Relapse for Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A UK Myeloma Research Alliance (UK-MRA) Real-World Multicentre Analysis. <i>Blood</i> , 2021, 138, 4120-4120.	1.4	3
165	Adaptation of the PERCEPT myeloma prehabilitation trial to virtual delivery: changes in response to the COVID-19 pandemic. <i>BMJ Open</i> , 2022, 12, e059516.	1.9	3
166	Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma. <i>British Journal of Haematology</i> , 2012, 157, 494-496.	2.5	2
167	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. , 0, , 121-133.		2
168	A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on <scp>ISS</scp> and <scp>PFS</scp>. <i>British Journal of Haematology</i> , 2019, 185, 350-353.	2.5	2
169	Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres. <i>British Journal of Haematology</i> , 2019, 186, 162-165.	2.5	2
170	Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 160-162.	0.9	2
171	The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study. <i>Supportive Care in Cancer</i> , 2022, 30, 7469-7479.	2.2	2
172	663. Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Reverse Osteoclast Activation in a Xenogeneic Murine Model of Multiple Myeloma. <i>Molecular Therapy</i> , 2006, 13, S256.	8.2	1
173	Solitary bone and extra-medullary plasmacytoma. , 0, , 167-173.		1
174	Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis – a first report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e309.	0.4	1
175	Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e5-e6.	0.4	1
176	How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. <i>Clinical Hematology International</i> , 2021, 3, 27.	1.7	1
177	BCMA CARs in multiple myeloma: room for more?. <i>Blood</i> , 2021, 137, 2859-2860.	1.4	1
178	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8034-8034.	1.6	1
179	Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 3023-3026.	1.3	1
180	CD26 Inhibition Can Aid the Homing of Cytokine Activated Mobilized Peripheral Blood (MPB) CD34+ Cells to the Bone Marrow (BM) but a Ligand Dependent Attachment Defect Prevents Their Long Term Retention and Subsequent Engraftment. <i>Blood</i> , 2011, 118, 141-141.	1.4	1

#	ARTICLE	IF	CITATIONS
181	A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial. <i>Blood</i> , 2013, 122, 765-765.	1.4	1
182	Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC). <i>Blood</i> , 2014, 124, 4745-4745.	1.4	1
183	Differential Expression of CD180 and sIgM by B Chronic Lymphocytic Leukaemia Cells (B-CLL) Using Mutated and Unmutated IgVh Genes.. <i>Blood</i> , 2004, 104, 2807-2807.	1.4	1
184	OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S2-S3.	0.4	1
185	Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients. <i>Blood</i> , 2021, 138, 458-458.	1.4	1
186	A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2676-2676.	1.4	1
187	Autologous Haematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia: A Single-Centre 18-Year Experience. <i>Blood</i> , 2021, 138, 3548-3548.	1.4	1
188	Relapsed multiple myeloma in the UK prior to the introduction of novel agents - a response to Koleva et al. (2010). <i>European Journal of Cancer Care</i> , 2011, 20, 697-699.	1.5	0
189	Epidemiology of myeloma. , 0, , 1-10.		0
190	Imaging of myeloma. , 0, , 28-38.		0
191	Cell cycle regulation and myeloma precursor cells. , 0, , 39-47.		0
192	The genetic and epigenetic mechanisms underlying the behavior of myeloma. , 0, , 48-63.		0
193	The myeloma bone marrow environment and survival signaling. , 0, , 64-83.		0
194	Immune dysfunction in multiple myeloma. , 0, , 84-95.		0
195	Myeloma bone disease “ pathogenesis of bone destruction and therapeutic strategies. , 0, , 96-109.		0
196	Principles of pathway directed therapy. , 0, , 110-120.		0
197	Multiple myeloma: management of de novo disease to include HDT. , 0, , 134-143.		0
198	Treatment of relapsed/refractory myeloma. , 0, , 144-166.		0

#	ARTICLE	IF	CITATIONS
199	Waldenstromâ€™s macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 190-215.		0
200	Treatment of emergent peripheral neuropathy in plasma cell disorders. , 0, , 245-254.		0
201	The management of infection in myeloma. , 0, , 276-287.		0
202	Diagnosis of myeloma and related plasma cell disorders. , 0, , 11-27.		0
203	Castlemanâ€™s disease. , 0, , 216-224.		0
204	POEMS syndrome and paraproteinemic syndromes: management and follow-up. , 0, , 225-244.		0
205	Management of renal failure in multiple myeloma. , 0, , 255-275.		0
206	Real World Data of the Impact of first cycle Daratumumab on Multiple Myeloma and Amyloidosis Services. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e157.	0.4	0
207	Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse. British Journal of Haematology, 2017, 177, 495-497.	2.5	0
208	Comparison of PET Reconstruction Algorithms on Assessment and Quantification of FDG-PETCT Findings in Patients with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e171.	0.4	0
209	Response to â€œImpact of immunosuppression on mortality in critically ill COVIDâ€™19 patientsâ€™. British Journal of Haematology, 2020, 191, 505-506.	2.5	0
210	A rare case of relapsed multiple myeloma with aberrant Tâ€™cell antigen expression and skin plasmacytomas. EJHaem, 2021, 2, 301-302.	1.0	0
211	Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience. Leukemia and Lymphoma, 2021, , 1-4.	1.3	0
212	Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. British Journal of Haematology, 2022, 196, .	2.5	0
213	Factors Influencing Short Term In Vivo Biodistribution of Human Bone Marrow Derived Mesenchymal Stem Cells (hMSCs) in a Xenogeneic Animal Model.. Blood, 2006, 108, 3182-3182.	1.4	0
214	Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.. Blood, 2006, 108, 505-505.	1.4	0
215	An Exercise Training Programme Produces Significant Improvements in Quality of Life (QoL), Muscle Strength and Cardiorespiratory Function in Patients with Myeloma.. Blood, 2007, 110, 3323-3323.	1.4	0
216	Outcomes in Relapsed Multiple Myeloma in the UK: A Retrospective Observational Study. Blood, 2008, 112, 4689-4689.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Proliferative Effect of APRIL On Primary Multiple Myeloma Cells Is Dictated by D-Type Cyclin Group and Translocation Status.. Blood, 2009, 114, 124-124.	1.4	0
218	An unusual case of myocardial infarction. BMJ Case Reports, 2010, 2010, bcr1120092422-bcr1120092422.	0.5	0
219	The Effect of Myeloma Cells on Bone Homeostasis Is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo. Blood, 2010, 116, 4052-4052.	1.4	0
220	An Alternate Day Dosing Strategy for Lenalidomide in Multiple Myeloma Improves Cost-Effectiveness Whilst Maintaining Efficacy,. Blood, 2011, 118, 4201-4201.	1.4	0
221	Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience. Blood, 2015, 126, 3180-3180.	1.4	0
222	POEMS Syndrome: Demographics and Outcomes in a United Kingdom Cohort. Blood, 2016, 128, 5582-5582.	1.4	0
223	Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma. Blood, 2018, 132, 3255-3255.	1.4	0
224	Encouraging Outcomes for Patients with Multiple Myeloma Treated in Early Phase Clinical Trials: A Single Centre and Meta-Analysis. Blood, 2018, 132, 5663-5663.	1.4	0
225	Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design. Blood, 2018, 132, 974-974.	1.4	0
226	Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide. Blood, 2019, 134, 4340-4340.	1.4	0
227	Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome. Blood, 2019, 134, 4368-4368.	1.4	0
228	Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study. Efficacy and Mechanism Evaluation, 2020, 7, 1-70.	0.7	0
229	Levofloxacin prophylaxis in patients with myeloma – Authors' reply. Lancet Oncology, The, 2020, 21, e69.	10.7	0
230	Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes. Blood, 2021, 138, 723-723.	1.4	0
231	Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk. Blood, 2021, 138, 2911-2911.	1.4	0
232	Autophagy Blockade Disrupts Myeloma Cell Recovery from Proteasome Inhibition and Enhances Apoptosis. Blood, 2021, 138, 1567-1567.	1.4	0
233	Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors. Blood, 2021, 138, 1628-1628.	1.4	0
234	Co-Operation of MCL-1 and BCL-X L Anti-Apoptotic Proteins in Stromal Protection of MM Cells from Carfilzomib Mediated Cytotoxicity. Blood, 2021, 138, 2677-2677.	1.4	0

#	ARTICLE	IF	CITATIONS
235	P-039: Adaptation of a myeloma minimal residual disease multi-parametric flow assay for real world practice. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S59-S60.	0.4	0
236	OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCoV-19 COVID-19 vaccines. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S30.	0.4	0
237	Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination. <i>Leukemia and Lymphoma</i> , 2022, , 1-5.	1.3	0